---
title: "AbbVie and Xilio Therapeutics announce collaboration and option agreement"
date: "2025-02-12 16:40:06"
summary: "AbbVie (NYSE:ABBV) and Xilio Therapeutics (NASDAQ:XLO) have entered into a collaboration and option-to-license agreement to develop innovative tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, using Xilio’s proprietary technology. Shares of Xilio surged 107% in premarket trading. As part of the agreement, Xilio will receive a total of $52 million in..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* AbbVie (NYSE:[ABBV](https://seekingalpha.com/symbol/ABBV "AbbVie Inc.")) and Xilio Therapeutics (NASDAQ:[XLO](https://seekingalpha.com/symbol/XLO "Xilio Therapeutics, Inc.")) have entered into a collaboration and option-to-license agreement to develop innovative tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, using Xilio’s proprietary technology.
* Shares of Xilio surged 107% in premarket trading.
* As part of the agreement, Xilio will receive a total of $52 million in upfront payments, which includes a $10 million equity investment.
* Additionally, Xilio will be eligible for up to approximately $2.1 billion in contingent payments tied to option-related fees and milestones, along with tiered royalties.
* Source: [Press Release](https://seekingalpha.com/pr/19999635-abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel)

[seekalpha](https://seekingalpha.com/news/4406805-abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement)
